← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Icogenex Corporation
Seattle, WA
$3,178,212
Total funding
8
Grants
Funding over time
peak $371.3K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$3,178,212 · 8
By mechanism
R43$1,477,960 · 6
R44$993,604 · 1
R01$706,648 · 1
Investigators at Icogenex Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel agonists and antogonists of chemokine receptors$504,143
R44 · FY2004 · AI
Novel agonists and antogonists of chemokine receptors$489,461
R44 · FY2003 · AI
Effector of APP to Lower Amount of beta-Amyloid Protein$369,888
R43 · FY2003 · AG
Alzheimer's Therapeutic Derived from a Natural Product$369,148
R43 · FY2005 · AG
Substrate Based Proteolytic Inhibitors for the Treatment of Huntington's Disease$361,935
R43 · FY2009 · NS
CONTROL OF IL-6 BY THROMBIN IN LUNG FIBROBLASTS$195,140
R01 · FY2002 · HL
CONTROL OF IL-6 BY THROMBIN IN LUNG FIBROBLASTS$189,455
R01 · FY2001 · HL
CONTROL OF IL-6 BY THROMBIN IN LUNG FIBROBLASTS$175,232
R01 · FY2003 · HL
AFFINITY AND TRANSCRIPTASE TECHNOLOGIES$172,431
R43 · FY2000 · CA
CONTROL OF IL-6 BY THROMBIN IN LUNG FIBROBLASTS$146,821
R01 · FY2000 · HL
NOVEL PEPTIDE INDUCERS OF GAMMA GLOBIN EXPRESSION$100,000
R43 · FY2000 · DK
Novel agonists and antagonists of chemokine receptors$95,223
R43 · FY2002 · AI
Substrate Based Proteolytic Inhibitors for the Treatment of Huntington's Disease$9,335
R43 · FY2009 · NS